Head-to-head · WeighScore
Bon Health vs Midi Health
The verdict
Bon Health takes it — 69.7/100 to 56.4/100.
Bon Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bon Health is a physician-led GLP-1 weight-loss telehealth service selling compounded semaglutide and tirzepatide on commitment tiers.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Bon Health | Midi Health |
|---|---|---|
| WeighScore | 69.7/100 | 56.4/100 |
| Grade | C | C |
| Scorecard rank | #113 | #413 |
| Semaglutide | $120/mo (12-month plan, compounded) | Not disclosed |
| Tirzepatide | $170/mo (12-month plan, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #113 · C
Strengths
- Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
- Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
- 24/7 physician support included free with your order; 1-3 day rapid dispatch
- Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered
Where it loses points
- The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
- The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro CTA reads 'Coming Soon' and points back to the compounded version
- Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
- The terms page returns a 404, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be read
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #413 · C
Strengths
- Available in all 50 states
- Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
- Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
- Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)
Where it loses points
- Does not accept Medicare, Medicaid, or Medi-Cal
- GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
- Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.